A Phase 4 interventional study of YMC026 and Placebo in Respiratory Disease, sponsored by Yuhan Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 15 Years to 74 Years. Per ClinicalTrials.gov, last updated 2019-01-16.
Sponsored by Yuhan Corporation · Phase 4, Interventional, and Treatment
Among 13 studies in Respiration Disorders with a site in Korea, Republic of — 1 open to participants now, 3 under way, 1 of them phase 3. Respiration Disorders · Korea, Republic of.
Among the 13 studies in Respiration Disorders with a site in Korea, Republic of, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2017, is the only one in phase 4, and was the 4th registered.
359 studies on the registry are indexed under Respiration Disorders; 64 are open to participants now.
Browse Respiration Disorders studies →1 of the 13 studies in Respiration Disorders with a site in Korea, Republic of is open now. Recruiting first, the newest first:
Seoul National University Hospital · Sites in Korea, Republic of
Ages up to 7 days · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 45 Respiration Disorders studies recruiting now, 27 (60%) set no upper age limit and 13 (29%) stop at 75 or younger; 15 take children under 18; 21 take healthy volunteers.
This study: 15 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 223 is above the median of 69 across 216 interventional studies indexed under Respiration Disorders.
Median enrollment 232 across the 10 interventional studies, 449 across the 3 observational. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 13 have an industry lead sponsor. The 10 most frequent:
Yuhan Corporation is the lead sponsor of 110 studies on the registry; 8 are open to participants now.
Yuhan Corporation has 1 study filed under Respiration Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Respiration Disorders with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 4, randomized, double-blind, multicenter clinical trial to evaluate the efficacy and safety of YMC026 in respiratory disease patients with cough and sputum as the main symptoms
The study has planned 4 visits during 2 weeks period (1 week of screening period, 1 week of treatment period). All subjects who agree to participate in the study and voluntarily give written informed consent are assessed by inclusion and exclusion criteria at the screening visit. After the screening period, the final eligibility of the subjects will be assessed at the randomization visit. Subjects who are determined to be appropriate for this study will be allocated to experimental group(YMC026) or control group(placebo) randomly in a 1:1 ratio. Subject will be administered the investigational product daily for 6 days. The safety for the subjects will be assessed at Day 3 and Day 6 visit, and the efficacy evaluation will be assessed at Day 6 visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
108 subjects will be assigned in this group. They will be administered 20mL of YMC026 three times a day for 6 days.
Drug: YMC026
108 subjects will be assigned in this group. They will be administered 20mL of placebo three times a day for 6 days.
Drug: Placebo
YMC026 20mL TID
Placebo 20mL TID
Change from Baseline BSS at Day 6
Bronchitis Severity Score
Time frame: Baseline(Day 0), Day 6
Change from Baseline BCSS at Day 6
Breathlessness, Cough, and Sputum Scale
Time frame: Baseline(Day 0), Day 6
Patients´ evaluation of symptoms of cough and sputum on patient's diary
Time frame: Day 6
Ran from Oct 2017 to primary completion in Apr 2018, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.